| Host |
Rabbit |
| Clone |
SP114 |
| Format |
Concentrate |
| Method |
P, WB |
| Pretreatment |
EDTA |
| Positive control |
Hodgkin´s Lymphoma |
| Dilution |
1:100 |
| Isotype |
Rabbit IgG |
| Immunogen |
Synthetic peptide near C-terminus of human MUM1/IRF4 |
| Localization |
Nucleus |
MUM1 / IRF4
|
Zytomed Systems GmbH |
SP114 |
1 ml |
Concentrate |
RUO |
513-4144 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Purified |
| Method |
P |
| Positive control |
infected tissue |
| Isotype |
Rabbit IgG |
| Immunogen |
Purified PPD from M. tuberculosis |
Mycobacterium tuberculosis
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
613-0282 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
- |
| Positive control |
Tubercolosis infected lung |
| Dilution |
1:500 - 1:1000 |
| Isotype |
not determined |
| Localization |
Bacterial rods and byproducts |
Mycobacterium tuberculosis
|
Biocare Medical |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
ACI140A |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
- |
| Positive control |
Tubercolosis infected lung |
| Dilution |
1:500 - 1:1000 |
| Isotype |
not determined |
| Localization |
Bacterial rods and byproducts |
Mycobacterium tuberculosis
|
Biocare Medical |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
ACI140C |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
- |
| Positive control |
Tubercolosis infected lung |
| Dilution |
- |
| Isotype |
not determined |
| Localization |
Bacterial rods and byproducts |
Mycobacterium tuberculosis
|
Biocare Medical |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
API140AA |
-
|
| Host |
Monospecific Rabbit |
| Clone |
ZR109 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Brain. |
| Dilution |
1:100 - 1:200 |
| Isotype |
Rabbit IgG |
| Immunogen |
Recombinant fragment (around aa 150-250) of human MBP |
| Localization |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZR109 |
1 ml |
Concentrate |
CE/IVD |
Z2411RL |
-
|
| Host |
Monospecific Rabbit |
| Clone |
ZR109 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Brain. |
| Dilution |
- |
| Isotype |
Rabbit IgG |
| Immunogen |
Recombinant fragment (around aa 150-250) of human MBP |
| Localization |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZR109 |
7 ml |
Ready-to-use |
CE/IVD |
Z2411RP |
-
|
| Host |
Monospecific Rabbit |
| Clone |
ZR109 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Brain. |
| Dilution |
1:100 - 1:200 |
| Isotype |
Rabbit IgG |
| Immunogen |
Recombinant fragment (around aa 150-250) of human MBP |
| Localization |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZR109 |
0.5 ml |
Concentrate |
CE/IVD |
Z2411RS |
-
|
| Host |
Monospecific Rabbit |
| Clone |
ZR109 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Brain. |
| Dilution |
1:100 - 1:200 |
| Isotype |
Rabbit IgG |
| Immunogen |
Recombinant fragment (around aa 150-250) of human MBP |
| Localization |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZR109 |
0.1 ml |
Concentrate |
CE/IVD |
Z2411RT |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM202 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Brain. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2a /κ |
| Immunogen |
Recombinant fragment (around aa 150-250) of human MBP |
| Localization |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZM202 |
1 ml |
Concentrate |
CE/IVD |
Z2485ML |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM202 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Brain. |
| Dilution |
- |
| Isotype |
IgG2a /κ |
| Immunogen |
Recombinant fragment (around aa 150-250) of human MBP |
| Localization |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZM202 |
7 ml |
Ready-to-use |
CE/IVD |
Z2485MP |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM202 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Brain. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2a /κ |
| Immunogen |
Recombinant fragment (around aa 150-250) of human MBP |
| Localization |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZM202 |
0.5 ml |
Concentrate |
CE/IVD |
Z2485MS |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM202 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Brain. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2a /κ |
| Immunogen |
Recombinant fragment (around aa 150-250) of human MBP |
| Localization |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZM202 |
0.1 ml |
Concentrate |
CE/IVD |
Z2485MT |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
N/A |
| Positive control |
Tissue with inflammatory proces (tonsil, colon cancer) |
| Dilution |
- |
| Isotype |
not determined |
| Localization |
Cytoplasmic |
Myeloperoxidase
|
Biocare Medical |
polyclonal |
25 ml |
Ready-to-use |
CE/IVD |
PP023H |
-
|
| Host |
Mouse |
| Clone |
ZM352 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Spleen, bone marrow |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b/κ |
| Immunogen |
Recombinant fragment (around aa150-250) of human MPO protein |
| Localization |
Cytoplasm |
Myeloperoxidase
|
Zeta Corporation |
ZM352 |
1 ml |
Concentrate |
CE/IVD |
Z2680ML |
-
|
| Host |
Mouse |
| Clone |
ZM352 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Positive control |
Spleen, bone marrow |
| Dilution |
- |
| Isotype |
IgG2b/κ |
| Immunogen |
Recombinant fragment (around aa150-250) of human MPO protein |
| Localization |
Cytoplasm |
Myeloperoxidase
|
Zeta Corporation |
ZM352 |
7 ml |
Ready-to-use |
CE/IVD |
Z2680MP |
-
|
| Host |
Mouse |
| Clone |
ZM352 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Spleen, bone marrow |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b/κ |
| Immunogen |
Recombinant fragment (around aa150-250) of human MPO protein |
| Localization |
Cytoplasm |
Myeloperoxidase
|
Zeta Corporation |
ZM352 |
0.5 ml |
Concentrate |
CE/IVD |
Z2680MS |
-
|
| Host |
Mouse |
| Clone |
ZM352 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Spleen, bone marrow |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b/κ |
| Immunogen |
Recombinant fragment (around aa150-250) of human MPO protein |
| Localization |
Cytoplasm |
Myeloperoxidase
|
Zeta Corporation |
ZM352 |
0.1 ml |
Concentrate |
CE/IVD |
Z2680MT |
-
|
| Host |
Mouse |
| Clone |
2C7 |
| Format |
Purified |
| Method |
F, P, EL, WB, FL |
| Positive control |
Bone Marrow |
| Dilution |
1:500 - 1:1000 (P) |
| Isotype |
Mouse IgG1 |
| Immunogen |
Human myeloperoxidase |
Myeloperoxidase (MPO, pANCA)
|
Zytomed Systems GmbH |
2C7 |
200 µg |
Purified |
RUO |
613-0318 |
-
|
| Host |
Mouse |
| Clone |
2C7 |
| Format |
Purified |
| Method |
F, P, FL |
| Positive control |
Bone Marrow |
| Dilution |
1:500 - 1:1000 (P) |
| Isotype |
Mouse IgG1 |
| Immunogen |
Human myeloperoxidase |
Myeloperoxidase (MPO, pANCA)
|
Zytomed Systems GmbH |
2C7 |
20 µg |
Purified |
RUO |
613-0319 |
-
|
| Host |
Rabbit |
| Clone |
SP72 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:100 |
| Isotype |
Rabbit IgG |
| Immunogen |
A synthetic peptide corresponding to C-terminus of human myeloperoxidase protein |
| Localization |
Cytoplasm |
Myeloperoxidase (MPO)
|
Zytomed Systems GmbH |
SP72 |
0.1 ml |
Concentrate |
RUO |
513-3720 |
-
|
| Host |
Mouse |
| Clone |
59A5 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG2b kappa |
| Immunogen |
Recombinant protein corresponding to 101 amino acids from exon 7 of human myeloperoxidase |
| Localization |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
59A5 |
1 ml |
Concentrate |
CE/IVD |
MOB551 |
-
|
| Host |
Mouse |
| Clone |
59A5 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG2b kappa |
| Immunogen |
Recombinant protein corresponding to 101 amino acids from exon 7 of human myeloperoxidase |
| Localization |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
59A5 |
0.1 ml |
Concentrate |
CE/IVD |
MOB551-01 |
-
|
| Host |
Mouse |
| Clone |
59A5 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG2b kappa |
| Immunogen |
Recombinant protein corresponding to 101 amino acids from exon 7 of human myeloperoxidase |
| Localization |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
59A5 |
0.5 ml |
Concentrate |
CE/IVD |
MOB551-05 |
-
|
| Host |
Mouse |
| Clone |
59A5 |
| Format |
Ready-to-use |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
- |
| Isotype |
Mouse IgG2b kappa |
| Immunogen |
Recombinant protein corresponding to 101 amino acids from exon 7 of human myeloperoxidase |
| Localization |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
59A5 |
6 ml |
Ready-to-use |
CE/IVD |
PDM551 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Ready-to-use |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
- |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR049 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:25 - 1:100 |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP053 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:25 - 1:100 |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP053-01 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:25 - 1:100 |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP053-05 |
-
|
| Host |
Mouse |
| Clone |
5.2F |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG2a |
| Localization |
Nucleus |
MyoD1
|
Diagnostic Biosystems |
5.2F |
1 ml |
Concentrate |
CE/IVD |
MOB278 |
-
|
| Host |
Mouse |
| Clone |
5.2F |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG2a |
| Localization |
Nucleus |
MyoD1
|
Diagnostic Biosystems |
5.2F |
0.1 ml |
Concentrate |
CE/IVD |
MOB278-01 |
-
|
| Host |
Mouse |
| Clone |
5.2F |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG2a |
| Localization |
Nucleus |
MyoD1
|
Diagnostic Biosystems |
5.2F |
0.5 ml |
Concentrate |
CE/IVD |
MOB278-05 |
-
|
| Host |
Mouse |
| Clone |
5.2F |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
- |
| Isotype |
Mouse IgG2a |
| Localization |
Nucleus |
MyoD1
|
Diagnostic Biosystems |
5.2F |
6 ml |
Ready-to-use |
CE/IVD |
PDM120 |
-
|
| Host |
Rabbit |
| Clone |
ZR262 |
| Format |
Concentrate |
| Method |
P |
| Positive control |
Rhabdomyosarcoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Localization |
Nuclear and cytoplasmic |
MyoD1
|
Zeta Corporation |
ZR262 |
1 ml |
Concentrate |
CE/IVD |
Z2576RL |
-
|
| Host |
Rabbit |
| Clone |
ZR262 |
| Format |
Ready-to-use |
| Method |
P |
| Positive control |
Rhabdomyosarcoma |
| Dilution |
RTU |
| Isotype |
IgG |
| Localization |
Nuclear and cytoplasmic |
MyoD1
|
Zeta Corporation |
ZR262 |
7.0 ml |
Ready-to-use |
CE/IVD |
Z2576RP |
-
|
| Host |
Rabbit |
| Clone |
ZR262 |
| Format |
Concentrate |
| Method |
P |
| Positive control |
Rhabdomyosarcoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Localization |
Nuclear and cytoplasmic |
MyoD1
|
Zeta Corporation |
ZR262 |
0.5 ml |
Concentrate |
CE/IVD |
Z2576RS |
-
|
| Host |
Rabbit |
| Clone |
ZR262 |
| Format |
Concentrate |
| Method |
P |
| Positive control |
Rhabdomyosarcoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Localization |
Nuclear and cytoplasmic |
MyoD1
|
Zeta Corporation |
ZR262 |
0.1 ml |
Concentrate |
CE/IVD |
Z2576RT |
-
|
| Host |
Mouse |
| Clone |
F5D |
| Format |
Concentrate |
| Method |
F, P, WB, IP, IF |
| Pretreatment |
Citrate |
| Positive control |
Rhabdomyosarcoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Localization |
Nucleus |
Myogenin
|
Diagnostic Biosystems |
F5D |
1 ml |
Concentrate |
CE/IVD |
MOB322 |
-
|
| Host |
Mouse |
| Clone |
F5D |
| Format |
Concentrate |
| Method |
F, P, WB, IP, IF |
| Pretreatment |
Citrate |
| Positive control |
Rhabdomyosarcoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Localization |
Nucleus |
Myogenin
|
Diagnostic Biosystems |
F5D |
0.1 ml |
Concentrate |
CE/IVD |
MOB322-01 |
-
|
| Host |
Mouse |
| Clone |
F5D |
| Format |
Concentrate |
| Method |
F, P, WB, IP, IF |
| Pretreatment |
Citrate |
| Positive control |
Rhabdomyosarcoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Localization |
Nucleus |
Myogenin
|
Diagnostic Biosystems |
F5D |
0.5 ml |
Concentrate |
CE/IVD |
MOB322-05 |
-
|
| Host |
Mouse |
| Clone |
F5D |
| Format |
Ready-to-use |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Rhabdomyosarcoma |
| Dilution |
- |
| Isotype |
Mouse IgG1 |
| Localization |
Nucleus |
Myogenin
|
Diagnostic Biosystems |
F5D |
6 ml |
Ready-to-use |
CE/IVD |
PDM158 |
-
|
| Host |
Mouse |
| Clone |
F5D |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Rhabdomyosarcoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant protein containing rat myogenin aa 30-224 |
| Localization |
Nucleus |
Myogenin
|
Zeta Corporation |
F5D |
1ml |
Concentrate |
CE/IVD |
Z2054ML |
-
|
| Host |
Mouse |
| Clone |
F5D |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Positive control |
Rhabdomyosarcoma. |
| Dilution |
- |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant protein containing rat myogenin aa 30-224 |
| Localization |
Nucleus |
Myogenin
|
Zeta Corporation |
F5D |
7 ml |
Ready-to-use |
CE/IVD |
Z2054MP |
-
|
| Host |
Mouse |
| Clone |
F5D |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Rhabdomyosarcoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant protein containing rat myogenin aa 30-224 |
| Localization |
Nucleus |
Myogenin
|
Zeta Corporation |
F5D |
0.5 ml |
Concentrate |
CE/IVD |
Z2054MS |
-
|
| Host |
Mouse |
| Clone |
F5D |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Rhabdomyosarcoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant protein containing rat myogenin aa 30-224 |
| Localization |
Nucleus |
Myogenin
|
Zeta Corporation |
F5D |
0.1 ml |
Concentrate |
CE/IVD |
Z2054MT |
-
|
| Host |
Mouse |
| Clone |
ZM149 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Rhabdomyosarcoma or Wilm's tumor. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Human myogenin recombinant protein |
| Localization |
Nucleus |
Myogenin
|
Zeta Corporation |
ZM149 |
1.0 ml |
Concentrate |
CE/IVD |
Z2462ML |
-
|
| Host |
Mouse |
| Clone |
ZM149 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Positive control |
Rhabdomyosarcoma or Wilm's tumor. |
| Dilution |
- |
| Isotype |
IgG1 /κ |
| Immunogen |
Human myogenin recombinant protein |
| Localization |
Nucleus |
Myogenin
|
Zeta Corporation |
ZM149 |
7 ml |
Ready-to-use |
CE/IVD |
Z2462MP |
-
|
| Host |
Mouse |
| Clone |
ZM149 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Rhabdomyosarcoma or Wilm's tumor. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Human myogenin recombinant protein |
| Localization |
Nucleus |
Myogenin
|
Zeta Corporation |
ZM149 |
0.5 ml |
Concentrate |
CE/IVD |
Z2462MS |
-
|
| Host |
Mouse |
| Clone |
ZM149 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Rhabdomyosarcoma or Wilm's tumor. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Human myogenin recombinant protein |
| Localization |
Nucleus |
Myogenin
|
Zeta Corporation |
ZM149 |
0.1 ml |
Concentrate |
CE/IVD |
Z2462MT |
-
|
| Host |
Mouse |
| Clone |
MY32 |
| Format |
Concentrate |
| Method |
F, P |
| Positive control |
Skeletal Muscle |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
Myosin (Skeletal Muscle)
|
Diagnostic Biosystems |
MY32 |
1 ml |
Concentrate |
CE/IVD |
MOB207 |
-
|